News
Stéphanie Moy
+33 (0)6 32 55 85 48
s.moy@quantumsurgical.com
Quantum Surgical receives the 2023 JFR Innovation Award from the French Society of Radiology and Medical Imaging
Montpellier, October 5, 2023 – French medical robotics company Quantum Surgical has been awarded the 2023 JFR Innovation Prize in the 'Interventional Imaging' category for its Epione® robot. Presented by the French Society of Radiology and Medical Imaging, this award recognizes industryl eaders who bring innovations to various areas of diagnostic and interventional medical imaging. Epione® enables early and minimally invasive treatment of abdominal and lung tumors. Quantum Surgical will participate in the Francophone Radiology Days (JFR) from October 13 to 16, 2023, at the Palais des Congrès inParis.
Quantum Surgical’s flagship product, the Epione® robotic platform is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors in the liver, kidney, pancreas and lung. Over 250 patients have already been treated in France and the United States.
The French Society of Radiology and Medical Imaging (SFR) has just awarded Quantum Surgical the 2023 JFR Innovation Prize in the 'Interventional Imaging' category for Epione®, its robotic solution for percutaneous multi-needle ablation of tumors located in the abdomen and lungs. Compatible with various ablation technologies, the Epione® solutions tandardizes the complex process of multi-needle placement and insertion by integrating specific functionalities into its software.
This allows for easier planning (based on a range of patterns predefined by the ablation needle manufacturer), precise targeting of complex tumors with accurate positions and oblique trajectories, and reduced needle insertion time thanks to automated robot arm positioning. Needles can then be placed with a reduced number of scans, limiting radiation exposure.
“We are very proud to receive the 2023 JFR Innovation Prize. At Quantum Surgical, we continuously develop features that improve both the user experience for physicians and that of the patients. We work hand in hand with healthcare professionals to better understand their needs and evolve our Epione® robot to meet them as effectively as possible,"says Bertin Nahum, President, and Co-founder of Quantum Surgical.
Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or their location.
Relying on the know-how of the physician, Epione® integrates all the steps of a percutaneous ablation procedure in a single platform: planning, targeting, ablation, confirmation.
A demonstration video of the Epione® robot isavailable here.
Quantum Surgical will participate in the Francophone Radiology Days from October 13 to 16, 2023, at the Palais des Congrès in Paris, located at Stand No. 14, 3rd floor, Interventional Radiology Village. The Innovation JFR Awards ceremony will take place on October 15 at 12:45 PM.
Quantum Surgical receives NMPA market authorization for its Epione® robot to treat abdominal cancers in China
Montpellier, September 21th 2023 - French medical robotics company Quantum Surgical has obtained market authorization from the National Medical Products Administration(NMPA) for the use and commercialization of its Epione® robot in China. Epione enables early and minimally invasive treatment of abdominal tumors. Nearly 610,000 new cases are diagnosed in China each year
Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.
Epione® can be used to treat abdominal tumors (including the liver, kidneys, and pancreas) and over 200 patients have already been treated in France and the United States.
The NMPA market authorization allows for offering this innovative, better targeted,and minimally invasive treatment to new patients in China, where nearly 610,000new cases of abdominal cancers are diagnosed each year.
"Thanks to the NMPA market authorization, we are very excited to be able to offer our Epione® solution to interventional oncologists in China. This is an important step that will provide Chinese patients with an innovative and minimally invasive treatment to treat their abdominal tumors at an early stage, while improving their comfort" says Bertin Nahum, President and Co-founder of Quantum Surgical.
"TheNMPA market authorization confirms the effectiveness of Epione® and, above all, the relevance of its deployment in China, where nearly 610,000 cases of abdominal cancers are diagnosed each year" explains Laetitia Messner, Chief Clinical Officer of Quantum Surgical.
Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, anavigation system and a camera.
Percutaneous ablation is an alternative to surgery in which a needle is inserted throughthe skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or their location.
Relying on the know-how of the physician, Epione® integrates all the steps of a percutaneous ablation procedure in a single platform: planning, targeting, ablation, confirmation.
[1] Globocan, 2020
Quantum Surgical sells its first Epione® robot in the US
Montpellier, December 11th 2023 – Popular Equipment Finance (DBA K2 Capital Group), a leader in equipment financing solutions in the US, has acquired Quantum Surgical’s Epione® robot. Popular Equipment Finance (DBA K2 Capital Group)works with top healthcare organizations across the U.S, including the renowned Cancer Center where Epione® was used in May 2023 to treat the first cancer patient in the territory.
The Epione® robotic platform is dedicated to the curative and early treatment of inoperable tumors in the abdomen (including liver, kidney and pancreas). A renowned cancer center in the US started using Epione® in May 2023 and has now entered a lease agreement with K2.
"It's very exciting that our group is the first in the Americas to use Epione® to treat abdominal tumors bringing such cutting-edge technology to mainstream clinical practice. The robot's accuracy is remarkable; we have shortened procedures times for complicated procedures and reduced radiation exposure for both the patient and the physician. Epione® is now part of our standard protocol for ablating abdominal tumors.” says Dr. Govindarajan Narayanan.
"The entire Quantum Surgical team is thrille dabout this first acquisition in the United States. Patient treatment and customer satisfaction are our priorities, and we are very proud of the positive feedback we’ve received from our users, which will help accelerate Epione®’s adoption in the US territory” says Bertin Nahum, President and Co-founder of Quantum Surgical.
As a reminder, Epione® is a robot-assisted technology designed to plan, target, perform, and confirm tumor ablation in the abdomen. Epione® allows physicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which one or more needles are inserted through the skin to the tumor to destroy it.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is also available at the Gustave Roussy Cancer Center in Villejuif, as well as at the Hospices Civils de Lyon. Over 300 patients have already been treated worldwide.
Quantum Surgical obtains CE mark approval to treat patients with lung tumors using its Epione® robot
Montpellier, September 7th 2023 – French medical robotics company Quantum Surgical has obtained CE mark approval for the expanded use of its robotic platform, Epione®, in the treatment of lung tumors. With over 2 million new cases worldwide in 2020, including approximately500,000 in Europe, lung cancer is the leading cause of cance- related mortality[1]. This new feature will be presented with related clinical study results at the CIRSE 2023 conference in Copenhagen from September 9th to 13th by Dr. Bonnet, interventional radiologist at Gustave Roussy.
Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allow sphysicians to treat inoperable tumors that are particularly difficult to reach,due to their size or their location, at an early stage, in a simple and effective way.
Epione® can be used to treat abdominal tumors (including theliver, kidneys, and pancreas) and over 200 patients have already been treated inFrance and the United States.
The CE mark approval for lung tumors will expand thisinnovative, targeted, and minimally invasive treatment to new patients inEurope.
It is based on a clinical study conducted at Gustave Roussy, the leading cancer center in Europe (third worldwide), the results of which will be presented during the international scientific conference organized by CIRSE(Cardiovascular and Interventional Radiological Society of Europe).
"With Epione®, our goal is to provide patients with an effective, better targeted and minimally invasive treatment. While over 2 million new cases of lung cancer diagnosed each year worldwide, we are delighted that our technology can now be accessible to new patients in Europe" said Bertin Nahum, President and Co-founder of Quantum Surgical.
“Patients were treated at Gustave Roussy with thermal destruction of lung metastases as part of a clinical study investigating the feasibility and safety of robotic guidance. In this ongoing study, the Epione® robot has consistently enabled technical success and has proven to be safe. The Epione® robot could enhance the minimally nvasive management of small and hard-to-reach lung tumors," stated Professor Thierry De Baère, Interventional Radiologist in the Department of Therapeutic Imaging at Gustave Roussy and member of the scientific advisory board of Quantum Surgical.
Laetitia Messner, Chief Clinical Officer of Quantum Surgical, explains, "Coordinated by Professor De Baère, the clinical study has demonstrated the clinical performance and safety of Epione® in the treatment of lung tumors. The CE mark approval proves the relevance and effectiveness of Epione®, which will enable us to offer innovative, targeted, and less invasive treatments to new patients."
Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or theirl ocation.
Relying on the know-how of the practitioner,Epione® integrates all the steps of a percutaneous ablation procedure in asingle platform: planning, targeting, ablation, confirmation.
[1] Globocan 2020
.jpg)
Cancer: 50 patients treated with the Epione® robot from Quantum Surgical at the Hospices Civils de Lyon
Montpellier, June 13, 2023 – A 50th patient has been treated using the Epione® robot from Quantum Surgical by the team of Pr. Laurent Milot, Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon (France), highlighting a successful collaboration only 8 months post-acquisition.
Installed in November 2022, the team of the Hospices Civils de Lyon (HCL, France) are convinced of the value of this innovative platform from Quantum Surgical and celebrating that 50 patients have benefited from Epione®.Epione® can be used to treat early-stage abdominal tumors that are inoperable or particularly difficult to reach, due to their size or location.
HCL is the second hospital in the world offering this revolutionary platform to their patients. The first Epione® robot was acquired by the Institut Gustave Roussy (France) in January 2022 where the team has already treated more than 100 patients. The very first patient in the United States was also successfully treated using the Epione® robot at Baptist Hospital in Miami (Florida) last month.
Beyond the new procedural advantages it provides, Epione® makes it possible to offer patients a minimally invasive treatment. It improves their comfort and facilitates their recovery, due to the absence of surgery.
For physicians and hospitals, Epione® combines advanced robotic assistance with image-guided navigation and ablation confirmation tools to promote the standardization of minimally invasive tumor ablation procedures. This is a major challenge given that more than 4 million abdominal cancers are diagnosed each year in the world[1].
“I am very pleased with this milestone, which above all underlines the perfect match between the HCL teams and the Epione® robot, which delivers all its promises. We are very excited to continue to explore the many benefits of Epione® and to support the next steps in the development of robotics in interventional radiology. This will undoubtedly lead to significant progress and extend hope for patients we do not have treatment solutions for so far” explains Prof. Laurent Milot, Deputy Chief Vascular & Interventional Radiology.
“The implementation of the Epione® robot within the Hospices Civils de Lyon is a success: in eight months, 50 patients have already benefited from our technology, as part of their cancer treatment. Pr. LaurentMilot's teams are particularly enthusiastic. We are delighted with this collaboration, which improves access to care and patient comfort” said Bertin Nahum, president and co-founder of Quantum Surgical.
[1] Source: GlobalCancer Observatory
First patient treated in the United States with Quantum Surgical’s Epione® robot
Montpellier, May 24, 2023 – Dr. Govindarajan Narayanan, chief of interventional oncology at Miami Cancer Institute and a vascular interventional radiologist with Miami Cardiac & Vascular Institute, successfully treated the first patient in the US with a liver tumor using Quantum Surgical’s Epione® robot. The procedure took place at Baptist Health South Florida in Miami, Florida, a few days after the Food and Drug Administration cleared Epione® robot for treatment of all abdominal cancers.
Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.
More than 150 patients have already been treated with the Epione® robot in Europe, and Dr. Narayanan successfully treated the first patient in the US.
“I am honored to be the first physician to utilize Epione® in the United States as this robotic-assisted equipment is going to change the way we deliver effective treatments to our patients for cancerous tumors,” said Dr. Narayanan. “Baptist Health has always been at the forefront when it comes to providing the very best care to the South Florida community and beyond. I am proud to be a part of such an incredible team.”
"We are very proud of this first intervention with our Epione® robot in the US! We are delighted to have been able to work with Dr. Narayanan and Baptist Health South Florida, renowned experts. This first intervention coincides with the FDA extension clearance to deploy our robotic solution in the United States. Dr. Narayanan is paving the way for physicians who will be able to offer more patients to benefit from innovative and less invasive treatments, and improve their lives" declares Bertin Nahum, President and co-founder of Quantum Surgical.
Epione® is a robot-assisted technology designed to plan, target, perform and confirm tumor ablation. Epione® enables physicians to perform percutaneous tumor ablations, a minimally invasive treatment in which one or more needles are inserted through the skin into the tumor to destroy it.
Epione® is currently available in Europe and the United States for treatment of all abdominal cancers. More than 4 million abdominal cancers occur each year worldwide[1].
[1] Source: Global Cancer Observatory
FDA clears Quantum Surgical’s Epione® robot for all abdominal cancers
Montpellier, May 3rd, 2023 - Quantum Surgical, a French medical robotics company, has received an extension of authorization from the US Food and Drug Administration (FDA) for its Epione® robot, which can now treat abdominal cancers. Millions of patients could benefit from Epione® treatment worldwide
Quantum Surgical’s flagship product, the Epione® robotic platform is dedicated to the curative treatment of cancers. Epione® allows physicians to treat tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.
Available in Europe and the United States, the Epione® robot has already been used to treat more than 150 patients with liver or kidney cancer.
The extension of the Food and Drug Administration (FDA) authorization allows the commercial sale and use of theEpione® robot in the United States to treat cancers of the entire abdomen. The abdomen is the space between the thorax and the pelvis, and includes in particular the following organs: liver, kidneys and adrenal glands, pancreas.
"We are very pleased to receive the FDA clearance. This decision allows physicians to now treat all abdominal tumors at an early stage and will accelerate the implementation of our innovative Epione® robotics solution in the United States. And ultimately, enable more patients to benefit from innovative and less invasive treatments" says Bertin Nahum, president and co-founder ofQuantum Surgical.
This authorization is supported by clinical data from the Gustave Roussy Cancer Center.
[1] Source: Global Cancer Observatory
Robert Thompson and Joseph de Vivo have joined Quantum Surgical’s Board of Directors
Montpellier, April 13th 2023 - Quantum Surgical, the Medical Robotic company dedicated to the curative and early treatment of cancers, has appointed Robert Thompson and Joseph de Vivo and on its Board of Directors as Independent Board Members.
Robert Thompson (Bob) is an accomplished marketing and business development leader and brings Quantum Surgical his experience in product development and commercialization in the medtech industry. He previously served as President-Ultrasound Siemens Healthineers, senior leadership positions at GE Healthcare and medical device start-ups.
“I am excited to join such a talented and visionary team. The innovative solutions developed by Quantum Surgical have the potential to transform cancer treatments by bringing a new standard of minimally invasive care of cancer patients worldwide” says Robert Thompson.
Joseph de Vivo brings over 30 years of experience in medical device, robotics and digital health industries. He was most recently Executive Chairman of Caption Health, President of Hospitals and Health Systems for Teladoc Health and CEO of In Touch Health. He previously served as CEO of Angiodynamics and President of Smith & Nephew Orthopedics. Mr De Vivo currently serves as the Treasurer of the American Telemedicine Association and on the Board of Governors for St Jude Children’s Research Hospital.
“The arrival of Robert and Joseph, two experienced healthtech leaders among our Board Members is a real opportunity for Quantum Surgical and will directly serve our strategy and our development, particularly in the United States”, said Bertin Nahum, CEO and Co-Founder of Quantum Surgical.
Quantum Surgical awarded prestigious Prix Galien USA 2022
Montpellier, France, October 28, 2022 - Quantum Surgical has been awarded the Prix Galien USA 2022, in the medtech start-up category, for its Epione® robotic platform, dedicated to the curative and early treatment of abdominal cancer and in particular liver cancer.
Considered to be the equivalent of the Nobel Prize in biopharmaceutical research, the Prix Galien highlights unique solutions and individuals who have influenced healthcare through innovation. Each year, the award recognises tomorrow's medical excellence in all areas of healthcare: drugs, medical devices and e-health.
The Prix Galien USA awards were presented to the winners on the evening of Thursday October 27 in New York at a ceremony at the Museum of Natural History.
"This award is an honor, and a recognition of the immense work Quantum Surgical has accomplished since 2017 without ever deviating from our mission: to provide access to minimally invasive treatments to as many cancer patients as possible. In five years, we have developed a robotic platform that is unique in the world, forged numerous scientific and commercial partnerships, and received support from international funds including Ally Bridge Group and the EIB. We have been able to deploy a new solution for curative and early treatment of abdominal cancers in Europe, the United States and China, alongside the most eminent interventional radiologists. I would like to pay tribute to them: they play an essential role in enabling cancer patients to benefit from innovative, better targeted and less aggressive treatments," says Bertin Nahum, co-founder and CEO of Quantum Surgical.
Thanks to the scientific partnerships developed by Quantum Surgical with the Montpellier University Hospital and the Gustave Roussy Institute in Villejuif, almost 100 patients with abdominal cancer have been treated with Epione® to date. Quantum Surgical plans to extend the indications of its technology to other cancers and to add decision support functions based on artificial intelligence algorithms. This is a public health issue, as the number of liver cancers in the world is expected to increase by 55% by 2040, as a study in theJ ournal of Hepatology recently pointed out.
Epione®, Quantum Surgical’s medical robot, settled in Hospices Civils de Lyon (HCL)
Montpellier, France November 16th, 2022 - Civil Hospitals of Lyon, France (HCL ) have aquired Epione, the robotic platform developed by Quantum Surgical (QS) that is designed to enable minimally invasive ablations of tumors in the abdomen. This partnership between HCL and QS will allow more patients to benefit from Epione, an innovative platform allowing physicians to plan, target, deliver and confirm ablation treatment in a moresecure and precise manner. Epione is currently utilized to target liver tumors but will be expanded to the treatment of kidney, lungs and pancreas as the radiologists at CHU Lyon expand their robotic interventional oncology practice.
HCL ranks asthe second largest University hospital in France and represents the second hospital in the world to offer this groundbreaking platform. The first Epione robot was acquired by Gustave Roussy in January 2022 and the team is approaching their 100throbotic procedure.
"This new acquisition of Epione is a major step for QS and a full validation of the key benefits that Epione offers. It is a great honor to have our robotic system acquired by one of the top medical robotic institutions in France. The most exciting part of this story is that patients will now have a powerful new technology that can offer curative treatments by robotically navigating to destroy tumors while sparing surrounding healthy tissue" says Bertin Nahum, co-founder and CEO of Quantum Surgical.
"Epione® is a unique percutanueous robotic solution […] Currently only few experts radiologists perform these treatments. Robotics will allow to standardize these treatments and more radiologists will thus be able to perform these cases especially the more complex cases on tumors which currently would not be treated . This will allow us to help and cure more patients" says Pr. Laurent Milot, deputy Head of Medical and interventional imagingDepartment- CHU Lyon.
Quantum Surgical announces the ongoing clinical trial at Gustave Roussy to extend the use of its medical robot Epione® in treating lung metastases
Montpellier, France, April 18th, 2023 - Quantum Surgical announces the ongoing clinical trial for the treatment of lung metastases assisted by the Epione® robot. The study is coordinated by Professor Thierry de Baère, Head of the Therapeutic Imaging Department at Gustave Roussy (Villejuif, France), ranked world's third best cancer hospital in 20231. This study will evaluate the clinical performance and safety of the Epione® device for the treatment of these tumors.
Epione® is a robotic platform capable of assisting interventional radiologists in planning and performing minimally invasive procedures for the percutaneous ablation of tumors in the abdomen. Available in France and the United States, the Epione® robot has already been used in procedures on more than 150 patients with liver or kidney cancer. With this study, Quantum Surgical aims to obtain an extension of its marketing authorizations in Europe and the United States with an indication extended to the treatment of lung tumors.
With more than 2 million new cases worldwide in 2020, including approximately 500,000 in Europe, lung cancer is the leading cause of death for cancer patients (18%)2.
"This study sets a new milestone in the development of Quantum Surgical, and I am proud that it is being done in collaboration with Gustave Roussy, whose teams see the full potential of our technology. This is another step towards the dissemination of our innovation to other cancer patients” says Bertin Nahum, President and co-founder of Quantum Surgical.
1 Gustave Roussy dans le TOP 3 mondial des hôpitaux en cancérologie | Gustave Roussy
%20(1)-min.png)
An exciting and busy year 2024 at Quantum Surgical
It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:
- The Paoli-Calmettes Institute in Marseille, France, acquired Epione. About 30 patients have since been treated by Dr Piana and his team.
- Quantum Surgical received €30 million financing from the European Investment Bank.
- Quantum Surgical launched the Epibone clinical study to assess Epione®’s performance to treat bone tumors.
- Rush University System for Health in Chicago (IL) acquired Epione®.
- Dr. Naranayan and his team celebrated the 150th patient treated at Baptist Health, Miami (FL).
- Quantum Surgical received the French National Institute of Industrial Property Award in the Start-up category.
- Quantum Surgical organized a webinar with the Baptist Health IO team.
- Quantum Surgical’s first symposiums took place in USA at Spectrum in Miami and in Europe at ECIO in Mallorca, Spain.
- Quantum Surgical obtained ISO 27001:2023 certification which attests to the security and rigor of its data management system.
- Bertin Nahum, CEO and co-founder, spoke at CES in Las Vegas, the biggest tech event in the world.
- Lucien Blondel, our CTO and co-founder, received the Surgical Robotics Industry Award of Industry Leadership.
- LSI Europe invited Quantum Surgical to present the Epione® solution in Lisbon, Portugal.
- Quantum Surgical and Epione® attended various events worldwide: Spectrum in Miami, FL; ECIO in Mallorca, Spain; CIRSE in Lisbon, Portugal; Medpeers in Amsterdam, The Netherlands…
- And 720+ patients have been treated overall!
We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!
‘I Literally Didn’t Have Any Organs Left to Take Out’: How Epione®, a Minimally Invasive Robotic-Assisted Ablation Technology Transformed a Cancer Patient’s Life
A groundbreaking achievement: Miami Cardiac and Vascular Institute and Miami Cancer Institute, part of Baptist Health South Florida, led the nation as the first to offer Epione, a cutting-edge robotic-assisted technology for minimally invasive ablation procedures. This technology has successfully transformed care for countless cancer patients.
For patients like Jose, the battle against renal cell carcinoma is a marathon, not a sprint. Diagnosed in 2006, Jose underwent a complete nephrectomy, removing his entire left kidney. Last year, his journey took another challenging turn when he developed metastatic lesions in the lower lobe of his right lung and pancreas, requiring additional surgeries. But when a lesion appeared in his remaining kidney, surgery was no longer an option.
Facing this new hurdle, Jose’s team at Miami Cancer Institute turned to innovation. They recommended a minimally invasive procedure using Epione, a robotic-assisted technology for percutaneous ablation. Given the tumor type and its location, the team decided that cryoablation would provide Jose with the best possible outcome.
Dr. Ripal Gandhi, a vascular and interventional radiologist with over 15 years of experience, led Jose’s procedure. A global thought leader in minimally invasive therapies, Dr. Gandhi specializes in cutting-edge treatments for cancer, peripheral vascular disease, and more. His expertise and Epione’s advanced technology offered Jose a new path forward in his ongoing fight against cancer.
“The benefits of the Epione robotic system is it allows us to treat patients more precisely, we are able to access lesions which sometimes would take us hours or sometimes we could not treat at all,” shared Dr. Gandhi. “It allows us to treat patients who may have a lot of issues, who might have a lot of comorbidities, who might not be safely placed under anesthesia for a long period of time, where you can treat the patient much faster and do it safely.”
For Dr. Gandhi and his colleagues at Miami Cancer Institute, Epione has been a ‘game-changing technology’.
“When we are doing procedures robotically versus freehand, these procedures are done much faster. It’s really beneficial for everybody; it’s beneficial for the patient as they are under anesthesia for a shorter period of time, and we are able to do more procedures in the room. Patients can have a faster recovery,” adds Dr. Gandhi.
Thanks to this minimally invasive, cutting-edge procedure, Jose has been given a renewed sense of hope and a cancer-free future. He and his family are deeply grateful to Dr. Gandhi and the team at Miami Cancer Institute for their exceptional care. At his most recent follow-up appointment, Jose was thrilled to share that he remains cancer-free, a testament to the power of innovation and expertise in modern medicine.
CIO 2025, October 17-19, 2025
CIO 2025 will be held in Miami, Florida, October 17 to 19.
The Symposium on Clinical Interventional Oncology (CIO) is the ultimate destination for clinicians passionate about advancing cancer through interventional oncology (IO).
Designed for practicioners at every stage of their IO journey, CIO delivers a comprehensive curriculum that spans foundational techniques to the latest innovations in robotics, systemic treatments, and emerging therapies.
Spend a weekend with experts in Miami and learn how the EPIONE® robotic platform will impact your clinical practice.
If you would like a more personalized demo, contact us at info@quantumsurgical.com and let the Quantum Surgical Team introduce you to EPIONE®, the all-in-one robotic platform designed to plan, target, deliver and confirm percutaneous ablation procedures..
We look forward to seeing you in Miami!
Event Details
Date :
- October 17-19, 2025
Location :
- Loews Miami Beach, Florida
JFR 2025, October 3-6
The Journées Francophones de Radiologie 2025 will be held from October 3rd to 6th in Palais des Congrès de Paris (Porte Maillot, Paris, France).
Do not miss your chance to meet with all the key players in Radiology!
Explore Epione®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.
- Visit us at Quantum Surgical Booth at the Village de Radiologie Interventionnelle (3rd floor).
- You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com
- You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com
- Discover Epione® during the Super Demo sessions hosted by some of our top users at the Agora of the Village de Radiologie Interventionnelle (information coming soon).
Event Details:
- Date: October 3-6th, 2025
- Location: Porte Maillot, Paris, France
- Learn more about the JFR 2025
WAIS 2025, September 20-24
WAIS 2025 will be held in Colorado Springs, CO, September 20-24, 2025.
The Western Angiographic & Interventional Society (WAIS) is celebrating its 55 year anniversary in 2025!
WAIS hosts an annual conference that focuses on a single general session format to connect faculty and attendees through interactive discussions and shared experiences. The 2025 Program is designed to address clinician practice gaps, as well as introduce emerging trends in image-guided therapies, patient care, and technology.
Quantum Surgical will exhibit Epione®, the all-in-one robotic-assisted solution which allows physicians to plan, target, deliver and confirm tumor ablation by combining the power of Navigation, Robotic-Assistance and Ablation Confirmation.
Please stop by our booth to meet with the Quantum Surgical team – we look forward to seeing you at the event!
Learn more about WAIS 2025.
Date:
- 20-24 September 2025
Location :
- The Broadmoor – Colorado Springs, Colorado
CIRSE 2025, September 13-17
Organized by the Cardiovascular and Interventional Radiology Society of Europe, the CIRSE 2025 event is the world's biggest meeting focusing on interventional radiology and will take place in Barcelona, Spain from September 13-17, 2025.
For 40 years, the CIRSE annual congress has provided the world’s premier platform for specialists in minimally invasive image-guided procedures to meet, share and connect. Quantum Surgical is delighted to announce its renewed participation this year, underscoring our commitment to advancing medical innovation and collaboration within this dynamic community.
Explore Epione®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.
Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com
Event Details:
- Date: September 13-17, 2025
- Location: Centre de Convencions International de Barcelona, Spain
ECIO 2025 - April 13-16, 2025
The European Conference on Interventional Oncology 2025 will be held in Rotterdam, The Netherlands, from April 13th to 16th, 2025.
Organized by the CIRSE, this yearly event brings together interventional radiologists, medical oncologists, surgeons, and numerous other healthcare professionals around the latest advancements in Interventional Oncology.
Don’t miss the opportunity to learn more about the Epione®, a unique robotic-assisted platform, at the ECIO:
- ORAL PRESENTATION – Preliminary results of the EPIBONE study
Dr. Baptiste Bonnet – Gustave Roussy (Villejuif, France)
Tuesday, April 15th I 8:30 AM – 10:00 AM
- ORAL PRESENTATION – Irreversible electroporation of liver lesions with robotic assistance: feasibility, safety and oncology outcome in a series of 22 cases
Prof. Laurent Milot – Hôpital Edouard Herriot, Hospices Civils de Lyon (Lyon, France)
Tuesday, April 15th I 5:00 PM – 6:30 PM
- e-POSTER – Safety and Accuracy of Robotic-Assisted Microwave ablation: first American experience on 50 patients
Dr. Govindarajan Narayanan – Baptist Health (Miami, USA)
- e-POSTER – Performance and safety of robotic-assisted CT-guided percutaneous ablation in lungs – Final results of the EGLE study
Dr. Baptiste Bonnet et al. – Gustave Roussy (Villejuif, France)
Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com
Détails de l'événement :
- Date: April 13-16, 2025
- Location: Rotterdam Ahoy Convention Centre – Rotterdam, The Netherlands
SIO 2025
The SIO 2025 Annual Scientific Meeting will be held in Las Vegas, NV, from January 30th to February 3rd, 2025.
We are excited to announce our active participation in the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting.
As a dedicated non-profit association, the Society of Interventional Oncology continues to champion the advancement of interventional oncology (IO), positioning it as the fourth pillar of cancer therapy worldwide. The SIO 2025 Annual Scientific Meeting stands as the pinnacle of gatherings in interventional oncology, showcasing the latest research, fostering longitudinal learning, hosting insightful tumor boards, and providing invaluable networking opportunities with colleagues and industry professionals.
Over the span of five enriching days, dive into a realm of new skills, forge meaningful relationships, and elevate patient-care practices. Join us at our booth for a firsthand experience of our groundbreaking solutions. Learn more about Epione®, our unique robotic-assisted platform that empowers physicians to Plan, Target, Deliver, and Confirm tumor ablation.
- Don’t miss the chance to register for the SIO hands-on workshops, designed to deepen your expertise:
“Robotics, Navigation, Guidance, and Confirmation Hands-on”: “Image Guidance & Robotics”
Sunday February 2nd, January 26th, 2:30pm – 3:45pm
Visit us at our booth throughout the event, from January 31st to February 2nd, for a captivating hands-on demonstration. Experience firsthand how Epione® is revolutionizing the field of interventional oncology.
Nous nous réjouissons de vous voir à cet événement.
To register for SIO 2025, please visit: Annual Scientific Meeting
Date :
- January 30th – February 2nd, 2025
Localisation :
- Paris Las Vegas, Las Vegas, Nevada
Stäubli Robotics and Quantum Surgical enter into a strategic partnership
Montpellier, France, June 23, 2020 - Stäubli Robotics and Quantum Surgical, both European leaders in their respective fields, are joining forces to create a Centre of excellence in oncology robotics.
Family-owned Stäubli Robotics, a division of the Stäubli Group, is a leading international player in industrial automation. Staubli Robotics designs, manufactures, and markets a complete range of robots adapted to all needs, even the most specific, such as in the field of medicine.
Quantum Surgical, an innovative surgical robotic company, is developing an innovative solution, a combination of powerful software and robotic platform for minimally invasive therapies in liver cancer.
This strategic partnership aims to combine this savoir-faire to strengthen the role of robotics in minimally invasive cancer treatments and to build a world leader.
A memorandum of understanding has been signed by the two parties.
"We are extremely grateful and proud that Quantum Surgical confirms their trust in Stäubli as a partner of choice for this new patient care application, at the service of human well-being. We are excited to contributing to Quantum's vision together, with a long-term partner that stimulates us on a daily basis and makes us better." announces Gerald Vogt, General Manager Stäubli Robotics.
"We are honored to work with Stäubli, a company recognized for its technological excellence and savoir-faire, in order to share a vision of robotics and automation in healthcare," explains Bertin Nahum, President, and Founder of Quantum Surgical.
World Premiere for Quantum Surgical's Medical Robot at Montpellier University Hospital
Montpellier, France, June 8, 2020 - On June 4, 2020, Professor Boris GUIU and his team at Montpellier University Hospital (France) successfully treated a 56-year-old patient with liver tumor using Quantum Surgical's medical robot.
Quantum Surgical, an innovative surgical robotic company founded in 2017, developed its robot in record time thanks to a highly talented and experienced multidisciplinary team.
This device, a combination of powerful software and robotic platform, assists the physician in performing safer, more efficient and less invasive oncology treatments.
Through Quantum Surgical’s device, Professor GUIU was able to plan the procedure on the patient's 3D images and then perform the intervention with high precision, guided by the robot.
This world premiere was accomplished as part of a clinical trial that is being carried out in three University Hospitals in France.
"This first thermoablation with robotic assistance completely treated the tumor with an excellent margin. We couldn't have done better. The patient is doing very well. He went home the very next day, ready to return to normal life," explains Professor Boris GUIU, Interventional Radiologist, Head of the Department of Diagnostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital)
"With this world premiere, Quantum Surgical is making a striking mark in the medical robotics industry and strengthening its ambition," announces Bertin NAHUM, President and Founder of Quantum Surgical.
Quantum Surgical expands its Scientific Advisory Board with Professor Kothary and Professor Colquhoun
Montpellier, France, June 2, 2020 - Quantum Surgical, an innovative surgical robotics company expands its Scientific Advisory Board (SAB) with the appointment of two leading North American physicians.
The Quantum Surgical Scientific Advisory Board (SAB) is a multi-disciplinary board composed of international experts in the field of image-guided interventional oncology:
• Professor Luigi Solbiati (IT), Interventional Radiologist, pioneer of percutaneous liver ab-lation techniques, Professor of Radiology at Humanitas University (Rozzano - Milan),
• Professor Boris Guiu (FR), Interventional Radiologist, Head of the Department of Diag-nostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital),
• Professor David C. Madoff (US), Interventional Radiologist at Yale New Haven Hospital (Yale University)
• Professor Nishita Kothary (US), Interventional Radiologist at Stanford University Medical Center (Stanford)
• Professor Steven D. Colquhoun (US), Liver surgeon, specialized in robotic surgery at UC Davis Comprehensive Cancer Center (Sacramento),
Professor Guy Vallancien (FR), urology surgeon, and pioneer of laparoscopic and robotic sur-gery, is an honorary member of this scientific advisory board.
Quantum Surgical is therefore reinforcing its collaboration with clinical experts as part of its devel-opment projects to strengthen its strategy with regard to the European and American markets.
"We are highly honored and delighted to be able to put to good use all the precious advice pro-vided by these internationally renowned physicians and be accompanied during the clinical development of our solution," explains Bertin Nahum, CEO, and co-founder of Quantum Surgical.
Quantum Surgical forms collaboration with PA-HP for AI Research in Ear-ly Cancer Treatment
Montpellier, France, February 11, 2020 – Quantum Surgical, an innovative company specializing in medical robotics, and AP-HP (Assistance Publique – Hôpitaux de Paris) have announced their collaboration on a future robotic solution.
This collaboration is part of a research project led by Professor Valérie Vilgrain, Head of the Radiology Department at Beaujon Hospital, AP-HP. The study is based on health data from patients admitted to AP-HP for liver tumor ablation, collected within the AP-HP’s Health Data Warehouse (EDS).
This partnership enables Quantum Surgical to access these data in order to develop and evaluate, together with radiologists, artificial intelligence algorithms aimed at facilitating minimally invasive treatments for liver cancer.
The project has received approval from the AP-HP EDS Scientific and Ethics Committee.
“We are honored and delighted by this collaboration. These data will allow us to expand use cases and advance medical image analysis as part of our artificial intelligence project,” said Bertin Nahum, President and Founder of Quantum Surgical.
“AI research is an excellent opportunity to foster academic–industry collaborations,” said Professor Valérie Vilgrain, Head of the Radiology Department at Beaujon Hospital, AP-HP.
Quantum Surgical receives €2 million from BpiFrance for the development of its next-gen robotized platform
Montpellier, France, Tuesday, January 21, 2020 – Quantum Surgical, an innovative company specializing in medical robotics, announces it has secured “Deeptech” development funding from Bpifrance for the development of its robotic platform designed to assist with minimally invasive surgical treatments in oncology.
This funding comes from Bpifrance’s “Deeptech” fund, which includes grants and repayable advances. Its objective is to support companies engaged in “Deeptech”-certified technological innovation projects involving industrial research and/or experimental development, with the aim of developing innovative products, processes, or services that offer tangible prospects for industrialization and commercialization.
“We are very pleased to receive this new support from Bpifrance, which is backing us in this exciting venture. This funding will allow us to accelerate the development of our innovative platform to benefit both patients and practitioners,” said Bertin Nahum, President and Founder of Quantum Surgical.
Quantum Surgical obtains ISO 13485: 2016 certification
Montpellier,November 28, 2019 - Quantum Surgical, an innovative surgical robotics company,today announced that it has obtained ISO 13485: 2016 certification for the"Design & development of computer assisted surgical systems" by TheCertification Body of TUV Rheinland.
This internationallyrecognized certification confirms that the quality management system meets thespecific standards required for the design and development of Quantum'stechnology.
"ObtainingISO 13485: 2016 certification is an important step for Quantum Surgical. It isan essential instrument to meet regulatory requirements and shows the company’sdetermination to be part of an industrial approach that meets the higheststandards of safety, performance and reliability” explains Bertin Nahum, CEOand co-founder of Quantum Surgical.
What isthe ISO 13485: 2016 standard?
The ISO13485: 2016 standard, recognized worldwide, specifies requirements for aquality management system where an organization needs to demonstrate itsability to provide medical devices and related services that consistently meetcustomer and applicable regulatory requirements. Such organizations can beinvolved in one or more stages of the life cycle, including design anddevelopment, production, storage and distribution, installation, or servicingof a medical device and design and development or provision of associatedactivities (e.g. technical support). ISO 13485:2016 can also be used bysuppliers or external parties that provide product, including qualitymanagement system-related services to such organizations.
Quantum Surgical and Montpellier-Nîmes Faculty of Medicine are co-developing a new training course
Montpellier, November 18, 2019 – For several months now, Quantum Surgical and the Faculty of Medicine Montpellier-Nîmes have been co-developing an unprecedented training program for companies, aimed at giving their employees a better understanding of the medical field. This hospital-university training program for companies will be led by professors, physicians, and healthcare professionals. Professor Michel Mondain, Dean of the Faculty of Medicine Montpellier-Nîmes, and Professor Boris Guiu, University Professor and Hospital Practitioner at Montpellier University Hospital and Head of Diagnostic and Interventional Radiology at Saint-Eloi Hospital, are working together to mobilize academic resources for the first session, scheduled for November 22.
This unique training program will initially offer two modules designed to strengthen employees' knowledge in the healthcare field. The first module will focus on foundational topics in surgery, anesthesia, and interventional radiology, leading into a more specialized section on liver cancer and percutaneous ablation.
This initiative reflects a strong commitment to fostering greater collaboration between healthcare professionals and those working on the technical side to build the medicine of tomorrow.
Founded in 2017 in Montpellier, Quantum Surgical is a French startup that puts innovation at the service of healthcare. With cutting-edge expertise and a team of sixty employees, the company is developing a unique solution dedicated to the minimally invasive treatment of liver cancer.
Quantum Surgical is committed to nurturing versatility and the sharing of expertise and experience within its teams. Through this initiative, the company aims to take its support for employees to the next level.
Aware of the major changes transforming the healthcare sector and the growing need for training among technical professionals, the Faculty of Medicine Montpellier-Nîmes is mobilizing its academic resources to meet the economic needs of industry. The Faculty has worked closely with Quantum Surgical to design a tailor-made training program aligned with the company’s specific needs.
Quantum Surgical establishes its Scientific Advisory Board (SAB) around international oncology experts
Montpellier, France, May 6, 2019 – Quantum Surgical, an innovative company specializing in medical robotics, announces the creation of its Scientific Advisory Board, which held its first meeting on April 8 in Amsterdam.
This Scientific Advisory Board is composed of leading multidisciplinary experts who are internationally recognized in the field of image-guided interventional oncology:
- Prof. Guy Vallancien (France) – Urological surgeon, pioneer in laparoscopic and robotic surgery, member of the French National Academy of Medicine, the Parliamentary Office for the Evaluation of Scientific and Technological Choices, and founder of the European School of Surgery;
- Prof. Luigi Solbiati (Italy) – Interventional radiologist, pioneer of percutaneous liver ablation techniques, former Head of the Oncologic Interventional Radiology Department at Busto Arsizio Hospital (Varese, Lombardy);
- Prof. David C. Madoff (USA) – Interventional radiologist, Vice Chair for Academic Affairs at NewYork-Presbyterian/Weill Cornell Hospital, and former Head of Interventional Radiology;
- Prof. Boris Guiu (France) – Interventional radiologist, Head of the Diagnostic and Interventional Radiology Department at Saint-Eloi Hospital – University Hospital of Montpellier, and Professor at the Faculty of Medicine in Montpellier.
The Quantum Surgical team will rely on these experts and benefit from their invaluable advice for the development and clinical launch of its product.
“We are honored to count such top-tier experts on our Scientific Advisory Board and are especially excited and grateful to benefit from their insights and invaluable clinical experience. This Scientific Advisory Board is essential for the next steps in Quantum Surgical’s development strategy,” said Bertin Nahum, President and Founder of Quantum Surgical.
Quantum Surgical, Ally Bridge and LifeTech Scientific announce Three-Way China Joint Venture to develop innovative surgical robot for the treatment of liver cancer
HONG KONG, SHENZHEN, China, and Montpellier, France, April 4, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, announced today that it has entered into an agreement with LifeTech Scientific Corporation (SEHK: 1302) (“LifeTech”), a leading medical device company in China, and Quantum Surgical, an innovative surgical robotics company in France, to establish a three-way China joint venture (“JV”). The JV will focus on the R&D and commercialization of Quantum Surgical’s integrated surgical robot platform in China for interventional oncology with the first target indication being liver cancer. China represents more than 50% of the world’s incidence of liver cancer.
The formation of this JV follows ABG’s Series A investment in Quantum Surgical (May 2018), in which LifeTech also participated in the investment through its existing partnership with ABG. ABG initiated and led the design and formation of the JV, where LifeTech is the majority shareholder and responsible for the setup and operation of the China JV, including contributing market know-how to expedite product approval and commercialization in China.
“ABG is excited to form this new China JV with LifeTech and Quantum Surgical, both of which are our portfolio companies. This JV showcases a new model for Sino-foreign collaboration in medical technologies. The ABG team has been working closely with Quantum Surgical, led by Bertin Nahum, following our successful investment in — and exit from – its predecessor company Medtech SA. Quantum Surgical is a natural extension of the 2018 ABG-led US$300 million investment in GRAIL, a healthcare company whose mission is to detect cancer early, when it can be cured. Early cancer detection must be accompanied by more effective early treatment, which Quantum is developing,” said Frank Yu, ABG’s Founder, CEO and CIO. “LifeTech has been a very close partner since the ABG team invested in the company’s IPO in 2011. LifeTech has a proven track record in obtaining “green channel” fast-track approval and commercializing in China for some of the world’s most innovative medical technologies. This includes collaborations with global medtech companies in localizing best-in-class products,
as proven by its China partnership with Medtronic, a critical strategy for foreign technologies entering the China market. This JV highlights ABG’s unique strategic and operational value-add for our portfolio companies in China, the U.S. and Europe, and how we invest in and bring cutting-edge technologies to solve large, poorly met medical needs in China,” Frank Yu added.
“This is a win-win partnership, where LifeTech Scientific is introduced and advised by our strategic partner ABG to join forces with Quantum Surgical, a leading innovative surgical robot developer with a proven track record,” said Yue-Hui Xie, Chairman and CEO of LifeTech Scientific. “This marks another ground-breaking achievement for LifeTech, investing in and partnering with world-leading healthcare technology following our strategic cooperation with ABG, including our participation in the 2018 financing for GRAIL. Both investments underpin LifeTech’s new strategic focus in cancer prevention and treatment,” Yue-Hui Xie added, “Following our successful partnership with U.S.-based global medtech giant Medtronic, our China JV with Quantum Surgical of France represents a new milestone for strategic and operational partnership with European companies in China.”
“Quantum will set new standards for minimally invasive cancer treatment procedures with the first target indication being liver cancer. We believe that LifeTech’s regulatory expertise and established commercialization infrastructure in China, coupled with ABG’s truly global industry network and strong capital markets and deal-making capabilities, will enable Quantum Surgical to accelerate its market entry into China and benefit millions of cancer patients there,” said Bertin Nahum, Founder and CEO of Quantum Surgical.
Quantum Surgical, award-winner of the Occitanie Innovation call for projects under the Investing for the Future scheme for its artificial intelligence program
Montpellier, France, Monday, February 4, 2019 – Quantum Surgical, an innovative company specializing in medical robotics, has been selected as a winner of the call for projects launched by the French government and the Occitanie Region as part of the third phase of the Programme d’Investissements d’Avenir (Investments for the Future Program), operated by Bpifrance, for the development of its artificial intelligence project.
The call for projects, “Occitanie Innovation Projects,” aims to accelerate the emergence and growth of regional companies that are leaders in their field and have the potential for national reach.
Quantum Surgical is receiving €490,000 in funding, equally financed by the French government and the Occitanie Region in the form of a grant.
With this funding, Quantum Surgical has launched a research and innovation program focused on artificial intelligence technologies to support the practice of percutaneous ablation.
“We are grateful for this continued support from the French government, the Occitanie Region, and Bpifrance, who remain by our side on this new journey. This will enable us to accelerate the development of innovative tools to benefit both patients and healthcare practitioners,” said Bertin Nahum, President and Founder of Quantum Surgical.
Quantum Surgical completes first round of financing to accelerate the development of its robotic platform for minimally invasive therapies in liver cancer
Montpellier and Hong Kong, June 4, 2018 – Quantum Surgical SAS, a company specializing in the design of next-generation solutions for the minimally invasive treatment of cancer, announces the completion of its first capital raise with Ally Bridge Group (ABG), a global investment group focused on life sciences. This Series A funding is the first tranche of a total $50 million financing round led by Ally Bridge Group.
Quantum Surgical is developing a next-generation robotic platform dedicated to the minimally invasive treatment of liver cancer. As this disease is the second leading cause of cancer-related death and affects more than 800,000 new patients each year worldwide, Quantum Surgical aims to provide healthcare professionals with new tools to better serve patients by offering a genuine alternative to current treatments.
“Quantum Surgical’s ambition is to establish new standards in cancer treatment by enabling more patients to access innovative, targeted, and less invasive therapies. We are thrilled to be working once again with Ally Bridge Group after our successful collaboration in 2015–2016. This new partnership will allow Quantum Surgical to leverage the group’s strong industrial outlook, international network, and solid financial capacity, as well as its expertise in accessing major medical markets such as the United States, China, and Europe,” said Bertin Nahum, Founder and President of Quantum Surgical.
“ABG is excited to support the Quantum Surgical team led by Bertin Nahum once again in their entrepreneurial journey, following our successful investment in Medtech SA. The team is recognized and has a proven track record in the development and global commercialization of innovative surgical robots. ABG has worked closely with Quantum Surgical since its inception. Our partnership is now at the forefront of creating next-generation robotics to support interventional oncology treatments, particularly for patients with early-stage cancer,” said Frank Yu, Founder and CEO of Ally Bridge Group. “Quantum Surgical is a natural extension of ABG’s recent $300 million investment in GRAIL, an innovative U.S. company focused on the early detection of cancer. ABG has the expertise to forge strategic partnerships between emerging companies and industry leaders at a global level, especially across the U.S., China, and Europe.”
Webinar on Robotics in Image Guided Ablation
Discover the power of Robotics in Image Guided Ablation during our upcoming webinar, featuring a live Q&A. Get your questions answered by experts from around the world. Don't miss this insightful session brought to you by Spectrum Cancer and Quantum Surgical.
Topics include:
- Benefits and challenges of robotics during ablation procedures
- Learning curves
- How to approach administration about adopting robotics
- Case presentations
- And live Q&A
Join us for this virtual event with live Q&A.
Limited spots.
REGISTER NOW!
Webinar on Robotic- Assisted Ablation for Abdominal Tumors: Expert Perspectives and Case Reviews
Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.
The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.
Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.
Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.
